Short communication. Differentiation of Type-I Porcine Reproductive and Respiratory Syndrome Virus vaccines and field strains by restriction fragment length polymorphism analysis

F. Diez-Fuertes^{*,1}, A. Vazquez^{1,2}, L. Hornillos-Gumiel¹, I. Simarro¹, J. M. Castro¹ and F. J. Martinez-Lobo¹

 ¹ SALUVET, Dpto. de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid. Avda. Puerta de Hierro s/n, Ciudad Universitaria, 28040 Madrid. Spain
 ² Centro Nacional de Microbiología-Instituto de Salud Carlos III. Ctra. Majadahonda-Pozuelo, km. 2. 28220 Majadahonda (Madrid). Spain

Abstract

The use of modified live virus (MLV) vaccines is a common procedure to control porcine reproductive and respiratory syndrome virus (PRRSV) infection in the great majority of countries from America, Asia and Europe, including Spain. Current discriminatory techniques allow the detection of different MLV type-II vaccine strains. Herein we report a rapid and accurate technique aimed to discriminate between MLV type-I vaccine strains and Spanish field strains. This technique comprises a reverse transcription (RT) and nested polymerase chain reaction (nPCR) amplification of PRRSV ORF5 followed by a digestion of RT-nPCR products with two specific endonucleases, *ItaI* and *AccI*. Combined utilization of *ItaI* and *AccI* generates restriction fragments length polymorphisms (RFLP) patterns adequate for the differentiation of 30 Spanish field isolates, of which 12 were isolated between 1991 and 1995 and 18 between 2000 and 2003. These different RFLP patterns can be used to distinguish unequivocally between Spanish field strains of PRRSV and the three MLV type-I vaccines used in Spain: AmervacPRRS®, Pyrsvac-183® and PorcilisPRRS®.

Additional key words: epidemiology; Europe; genomic variability; heterogeneity; PRRSV; RFLP; Spain.

Resumen

Comunicación corta. Diferenciación de cepas vacunales del virus del síndrome reproductor y respiratorio porcino de tipo I y cepas de campo por análisis de polimorfismos en la longitud de fragmentos de restricción

Para controlar la infección por el virus del síndrome reproductor y respiratorio porcino (PRRSV), en la gran mayoría de países de América, Asia y Europa, incluyendo España, se usan frecuentemente vacunas basadas en virus vivos modificados (MLV). En la actualidad existen técnicas discriminatorias que permiten detectar cepas vacunales del PRRSV de tipo II. El presente trabajo describe una técnica precisa y rápida para la diferenciación de cepas vacunales de tipo I del PRRSV y cepas de campo españolas. Esta técnica se basa en la transcripción reversa y posterior amplificación de la ORF5 del genoma del PRRSV utilizando la reacción en cadena de la polimerasa anidada, seguida de la digestión de los amplicones generados con dos endonucleasas específicas: *Ita*I y *Acc*I. La utilización combinada de ambas enzimas genera patrones de polimorfismos en la longitud de fragmentos de restricción (RFLP), adecuados para la distinción de las 30 cepas de campo usadas, de las cuales 12 fueron aisladas entre 1991 y 1995 y 18 entre 2000 y 2003. Estos diferentes patrones pueden ser utilizados para distinguir entre cepas de campo españolas del PRRSV y las tres cepas vacunales de tipo I usadas en España: AmervacPRRS®, Pyrsvac-183® y PorcilisPRRS®.

Palabras clave adicionales: epidemiología; España; Europa; heterogeneidad; PRRSV; RFLP; variabilidad genómica.

^{*}Corresponding author: fdiez@vet.ucm.es Received: 25-05-11. Accepted: 20-12-11

Abbreviations used: MLV (modified live virus), nPCR (nested polymerase chain reaction), PRRS (porcine reproductive and respiratory syndrome), PRRSV (porcine reproductive and respiratory syndrome virus), RFLP (restriction fragments length polymorphisms), RT-PCR (reverse transcription polymerase chain reaction).

Porcine reproductive and respiratory syndrome (PRRS) is one of the most relevant swine diseases, characterized by reproductive failure in sows and respiratory distress in pigs of all ages (Rossow, 1998). The causative agent, PRRS virus (PRRSV), is a small, enveloped RNA virus classified within the *Arteriviridae* family (Cavanagh, 1997) which is divided into type-I and type-II based on the high genetic, antigenic and pathogenic heterogeneity among different viral isolates (Meng, 2000).

The diagnosis of PRRSV infection is frequently based on the detection of a portion of PRRSV genome by reverse transcription polymerase chain reaction (RT-PCR) in clinical samples (Suárez et al., 1994; Christopher-Henning et al., 1995). The extensive use of modified live virus (MLV) vaccines for the control of PRRS, both in growing and breeding pigs, might hinder the diagnosis of the disease. Furthermore, all available MLV vaccines based either on type-I or type-II strains induce a longlasting viremia in vaccinated pigs similar to that produced by field viruses (Mengeling et al., 1999; Scortti et al., 2006). Therefore, a rapid, sensitive and accurate technique that allows the discrimination between vaccine and field strains of PRRSV is necessary. In those lines, a test based on the patterns produced by digestion of PCR products with different restriction enzymes has been developed for the differentiation of type-II field strains and Ingelvac PRRS MLV/ReproTM, a MLV type-II vaccine frequently used for the control of the disease (Wesley et al., 1998). This method has frequently been used to typify PRRSV type-II isolates (Cai et al., 2002; Brar et al., 2011). Nonetheless, the extensive genetic differences between type-I and type-II strains of PRRSV make the application of this technique useless in the European situation.

The present study describes an easy and fast technique that discriminates MLV type-I vaccine strains from field strains, by means of RT and nested polymerase chain reaction (nPCR) amplification of PRRSV ORF5 and restriction fragment length polymorphisms (RFLP) analysis of RT-nPCR products digested with specific endonucleases. To determine which restriction enzymes would differentiate MLV type-I vaccine strains from field strains, PRRSV type-I ORF5 sequences were obtained from nucleotide data bases (EMBL/GenBank libraries) and restriction patterns for different enzymes examined using WebCutter 2.0 software (http://rna.lundberg.gu.se/ cutter2). ItaI was selected on the basis of predicted cutting patterns. Later on, a second restriction enzyme -AccI- was chosen to determine a second RFLP pattern for a particular group of strains that shared the same RFLP pattern than one of the MLV type-I vaccine.

To validate the technique, RFLP patterns of 30 Spanish PRRSV isolates were compared to those of the three MLV type-I vaccines (AmervacPRRS[®]), Pyrsvac-183® and PorcilisPRRS®). For this purpose, RNA was extracted using Chelex® 100 resin (BioRad, Hercules, CA, USA) as described Walsh et al. (1991). The RT-PCR was performed using a commercial onestep RT-PCR kit (GeneAmp® Gold RNA PCR Core kit, Applied Biosystems, Foster City, CA, USA), following the manufacturer's instructions. Primers used to amplify the whole ORF5 and the flanking regions of ORF4 and ORF6 were previously reported by Prieto et al. (2009). Second round PCR amplification was performed following a preceding technique (Suárez et al., 1994). An amplicon of 606 bp than comprises the whole ORF5 was obtained. The restriction enzyme Ital (Roche, Basel, Switzerland) was used to digest the products of the second round PCR. For this purpose, 14 µL of each PCR product were incubated at 37°C overnight in a digestion mixture containing 3 U of the enzyme and 2 μ L of the corresponding buffer in a final volume of 20 µL. The products of digestion were visualized by electrophoresis at 50 V for 3 hours in 3% agarose gels (AG5, Ecogen, Spain) prepared in TBE 1x. Quantity One BioRad software version 4.2.1. (BioRad, Hercules, CA, USA) was used to predict the size of the bands on agarose gels. When RFLP patterns obtained after digestion with Ital were the same for field isolates and one of the MLV vaccine strains used -PorcilisPRRS[®], a second digestion with the restriction enzyme AccI (Roche, Basel, Switzerland) was performed in the above mentioned conditions.

The restriction enzyme *ItaI* cut ORF5 of all strains tested, including field and vaccine strains, at least once (Fig. 1a and 1b). A total of 18 different RFLP patterns were obtained. Some of them were very alike —*i.e.* patterns 2, 9 and 11. Of the 18 patterns found, pattern 1 corresponded to two Spanish MLV vaccines —AmervacPRRS® and Pyrsvac-183®—, pattern 2 corresponded to PorcilisPRRS® vaccine strain, and the sixteen additional RFLP patterns corresponded to the Spanish field PRRSV strains. The number of RFLP patterns obtained for recently isolated field viruses (Fig. 1a) —15 patterns in 18 strains tested— is higher than the number of RFLP patterns for isolates obtained in the first few years after the description of the disease (Fig. 1b) —6 in 12 strains tested—.

Comparison of RFLP patterns obtained by digestion of vaccine strains and field isolates with *ItaI* shows that most of the field isolates tested exhibited RFLP patterns




Figure 1. Restriction fragment length polymorphism (RFLP) patterns obtained after digestion with *ItaI* of vaccine strains and Spanish PRRSV strains isolated between 2000 and 2003 (1a) or between 1991 and 1995 (1b). RFLP patterns obtained after digestion with *AccI* of PorcilisPRRS® and field isolates that showed RFLP pattern 2 after cut with *ItaI* (1c). The numbers indicate the different patterns obtained for these PRRSV strains. The total number of RFLP patterns was 15 for strains isolated between 2000 and 2003 and 6 for strains isolated between 1991 and 1995. The first patterns correspond to vaccine strains, AmervacPRRS®, Pyrsvac-183® and PorcilisPRRS®, respectively.

distinguishable from vaccine strains. However, one field isolate exhibited RFLP pattern 1 while three of them showed RFLP pattern 2. The only isolate that exhibited the same RFLP pattern than the Spanish vaccine strains (pattern 1) was isolated from a herd that has started vaccination with a MLV Spanish vaccine a few months earlier. To study whether this isolate had a vaccine origin, the PCR product of ORF5 was sequenced and compared to ORF5 of the Spanish vaccine strain used in the farm. A percentage of similarity of 99.5% seems to confirm that this isolate derivates from the vaccine strain used in the farm (Fig. 2). A similar result has been previously reported between Porcilis PRRS® strain and field isolates showing close phylogenetic relationships (Pesente et al., 2006). However, the digestion of RT-PCR products of isolates that shared the RFLP pattern 2 when cut with ItaI with a second restriction enzyme, AccI, rendered different patterns indicating that those field isolates are different from the vaccine strain. Accordingly, pattern 1 corresponded to the vaccine strain while pattern 2 was shared by two recent field isolates and pattern 3 was found in one early isolate (Fig. 1c).

The study of RFLP patterns of field PRRSV isolates could be a first approach to discard the vaccine origin of a strain implicated in an outbreak of the disease. The usefulness of this approach has been confirmed for type-II strains using 3 different restriction enzymes (Wesley et al., 1998). The present study confirms that an analogous technique can be applied to type-I strains. Thus, the digestion of PCR products of PRRSV type-I ORF5 with only one or, occasionally, two restriction enzymes (ItaI and AccI), differentiates efficiently vaccines and field strains. Increasing the number of strains with representatives of different countries would confirm the usefulness of this technique in epidemiologic studies. Furthermore, the fact that the number of RFLP patterns found in isolates of recent years is higher than in those from early years, after the description of the disease, indicates a continuous genetic drift that increases genetic diversity. This scenario has been previously documented (Wesley et al., 1999; Prieto et al., 2009).

In conclusion, RFLP analyses of PRRSV type-I isolates can be considered an useful, fast and convenient method to discriminate between field and vaccine

```
001 ATGAGATGTT CTCACAAATT GGAGCGTTTC TTGACTCCTC ACTCTTGCTT 050
001 ----- 050
051 CTGGTGGCTT TTTTTGCTTT GTACCGGCTT GTCTTGGTCC TTTGTCGATG 100
051 ----- G- ----- 100
101 GCAACGACAG CAGCTCGACA TACCAATACA TATATAATTT GACGATATGC 150
101 ---
                                           ---- 150
151 GAGCTGAATG GGACCGAATG GTTGCCCAGC CATTTTGACT GGGCAGTCGA 200
151 ----- 200
201 GACCTTTGTG CTTTACCCGG TTGCCACTCA TATCCTTTCA CTGGGTTTTC 250
201 -----
                                         ----- 250
            251 TCACAACAAG CCATTTTTTT GATGCGCTCG GTCTCGGCGC TGTGTCCACT 300
251 -----
                                              -- 300
301 ACAGGATTTG TTGGCGGGCG GTATGTACTC AGCAGCGTGT ACGGCGCTTG 350
301
                                               - 350
351 TGCTTTCGCA GCGCTCGTAT GTTTTGTCAT CCGCGCTGCT AAAAATTGCA 400
351 --
                                            ---- 400
       401 TGGCTTGCCG TTATGCCCGT ACCCGGTTTA CCAACTTCAT TGTGGACGAC 450
401 -----
                                             --- 450
451 CGGGGGAGGA TCCATCGATG GAAGTCTCCA ATAGTGGTAG AGAAATTGGG 500
451 -
                                              -- 500
501 CAAAGCTGAA GTCGGTGGCG ACCTCGTCAC CATCAAACAT GTCGTCCTCG 550
                                                550
551 AAGGGGTTAA AGCTCAACCC TTGACGAGGA CTTCGGCTGA GCAATGGGAA 600
551 ---
                                                600
601 GCCTAG
                                                 606
601 -
                                                 606
```

Figure 2. Comparison of the sequences of AmervacPRRS® ORF5 (above) and PRRSV-16 ORF5 (below), respectively. The 99.5% sequence similarity would confirm that the field isolate PRRSV-16 derivates from the vaccine strain used a few months earlier for the vaccination of the same herd.

viruses, although additional studies comprising more isolates should be performed to give strength to the technique. Additionally, the study of RFLP patterns could be useful in epidemiological studies, although a thoughtful study should include sequencing approaches to characterize unequivocally every PRRSV strain.

Acknowledgements

This study was supported by grants AGL2001-2055 and AGL2005-04281 from the Spanish CICYT. Javier Martínez-Lobo was supported by a predoctoral fellowship of the Comunidad Autónoma de Madrid and Francisco Díez-Fuertes by a predoctoral fellowship of the Spanish Ministry of Science and Innovation.

References

Brar MS, Shi M, Ge L, Carman S, Murtaugh MP, Leung FC, 2011. Porcine reproductive and respiratory syndrome virus in Ontario, Canada 1999-2010: genetic diversity and re-

striction fragment length polymorphisms. J Gen Virol 92(6): 1391-1397.

- Cai HY, Alexander H, Carman S, Lloyd D, Josephson G, Maxie MG, 2002. Restriction fragment length polymorphism of porcine reproductive and respiratory syndrome viruses recovered from Ontario farms, 1998-2000. J Vet Diag In 14: 343-347.
- Cavanagh D, 1997. Nidovirales: a new order comprising Coronaviridae and Arteriviridae. Arch Virol 142(3): 629-633.
- Christopher-Hennings J, Nelson EA, Nelson JK, Hines RJ, Swenson SL, Hill HT, Zimmerman JJ, Katz JB, Yaeger MJ, Chase CC, 1995. Detection of porcine reproductive and respiratory syndrome virus in boar semen by PCR. J ClinMicrobiol 33(7): 1730-1734.
- Meng XJ, 2000. Heterogeneity of PRRSV: implications of current vaccine efficacy and future development. Vet Microbiol 74: 309-329.
- Mengeling WL, Lager KM, Vorwald AC, 1999. Safety and efficacy of vaccination of pregnant gilts against porcine reproductive and respiratory syndrome. Am J Vet Res 60(7): 796-801.
- Pesente P, Rebonato V, Sandri G, Giovanardi D, Ruffoni LS, Torriani S, 2006. Phylogenetic analysis of ORF5 and ORF7 sequences of porcine reproductive and respiratory syndrome virus (PRRSV) from PRRS-positive Italian farms: A showcase for PRRSV epidemiology and its consequences on farm management. VetMicrobiol 114: 214-224.
- Prieto C, Vázquez A, Núñez JI, Álvarez E, Simarro I, Castro JM, 2009. Influence of time on the genetic heterogeneity of Spanish porcine reproductive and respiratory syndrome virus isolates. Vet J 180: 363-370.
- Rossow KD, 1998. Porcine reproductive and respiratory syndrome. Vet Pathol 35: 1-20.
- Scortti M, Prieto C, Martínez-Lobo FJ, Simarro I, Castro JM, 2006. Effects of two commercial European modified-live vaccines against porcine reproductive and respiratory syndrome viruses in pregnant gilts. Vet J 172: 506-514.
- Suárez P, Zardoya R, Prieto C, Solana A, Tabarés E, Bautista JM, Castro JM, 1994. Direct detection of the porcine reproductive and respiratory syndrome (PRRS) virus by reverse polymerase chain reaction (RT-PCR). Arch Virol 135(1-2): 89-99.
- Walsh PS, Metzger DA, Higuchi R, 1991. Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. Biotechniques 10(4): 506-513.
- Wesley RD, Mengeling WL, Lager KM, Clouser DF, Landgraf JG, Frey ML, 1998. Differentiation of a porcine reproductive and respiratory syndrome virus vaccine strain from North American field strains by restriction fragment length polymorphism analysis of ORF 5. J Vet Diag In 10: 140-144.
- Wesley RD, Mengeling WL, Lager KM, Vorwald AC, Roof MB, 1999. Evidence for divergence of restriction fragment length polymorphism patterns following in vivo replication of porcine reproductive and respiratory syndrome virus. Am J Vet Res 60(4): 463-467.